Previous attempts at creating wide-spectrum anti-viral drugs have largely failed. Some are in use, but they are very expensive, and because they work by attacking RNA and DNA replication, they often carry significant side effects. By attacking the structure of the viruses, not the replication, LJ001 may end up as the first drug in a new age of medicine.